Decision Resources announced today the release of its new report focusing on non-small-cell lung cancer. The study found that AstraZeneca is set to make a dramatic entrance into the non-small-cell cancer arena with gefitinib, a preregistered epidermal growth factor receptor tyrosine kinase inhibitor. Thought leaders interviewed for this study say gefitinib promises the advantages of improved efficacy in the late-stage setting of non-small-cell lung cancer and an extremely favorable toxicity profile.

(Photo: )

"The great news about AstraZeneca's gefitinib is that the favorable toxicity profile will allow a large, currently untreated population to become eligible for treatment," said Mary Fletcher-Louis, analyst, Decision Resources. "We conclude that peak year sales for gefitinib will be in the range of $3 to $3.4 billion for non-small-cell lung cancer alone."

The report entitled Non-Small-Cell Lung Cancer also discusses key unmet needs in the non-small-cell lung cancer market, current and emerging therapies, and the total market outlook. Companies making significant contributions to this market, such as AstraZeneca, Eli Lilly and Bristol-Myers Squibb, are profiled in the report.

Disease Facts - Non-Small-Cell Lung Cancer

Lung cancer is the most frequently diagnosed cancer in the United States and Europe, and it is the leading cause of cancer mortality in the seven major pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). Despite strong public awareness of an established link between smoking and the development of lung cancer, incidence continues to rise. Non-small-cell lung cancer (NSCLC) accounts for 80-85% of all lung cancers, with the remaining cancers classified as small-cell lung cancer or other, rarer histologies. NSCLC is distinguished by huge unmet need for more- effective therapies - only a minority of patients lives for more than one year after diagnosis, and the five year survival rate is less than 15%. The number of incident cases of non-small-cell lung cancer in 2001 totaled 208,100 in the major pharmaceutical markets. Because of population growth and age redistribution (i.e. growth in the elderly population), this total will increase to 239,400 in 2011.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Diseases, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Cardium focuses on indications and issues of interest within the cardiovascular therapeutic area; Non-Small- Cell Lung Cancer is an Onkos report.

About Decision Resources

Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The Company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:     Elizabeth Marshall    Decision Resources    781-296-2563 


Photo: NewsCom:

AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563, or

Biogen's Leading Multiple Sclerosis Drug May Lose Its Dominance To Ares-Serono's New Therapy

View Now